SKNV Gears Up to Increase Production Capacity Resulting from FDA's Recent Warnings
POMPANO BEACH, Fla., April 4, 2024 /PRNewswire/ -- SKNV is increasing its manufacturing capacity to meet the growing demands of healthcare providers for topical numbing creams to support the FDA's recent efforts to combat unapproved and misbranded over-the-counter analgesic products. The Agency's warnings underscore the importance of prescribing Rx medications made from FDA-registered 503B outsourcing facilities, such as SKNV. SKNV's various prescription-based numbing formulations that offer different levels of potency are only made available to registered physicians at www.sknvnumbingcream.com.
- SKNV supports FDA's efforts to combat adverse effects associated with the use of OTC topical numbing creams for dermatologic procedures.
- The Agency's warnings underscore the importance of prescribing Rx medications made from FDA-registered 503B outsourcing facilities, such as SKNV.
- SKNV, an FDA-Registered 503B Outsourcing Facility, plays a critical role in ensuring that patients have access to quality topical numbing medications.
- "SKNV manufactures a broad variety of topical numbing formulations providing prescribers a wide selection of solutions to choose from.